Overview

Expanded Access Treatment Protocol: Remdesivir for the Treatment of SARS-CoV2 (CoV) Infection 

Due to the lack of proven treatment options for COVID-19, the only medical intervention currently available to patients who develop severe or life-threatening illness is supportive care. Developing and researching potential treatments in an expedited fashion is a priority in combating this disease. Remdesivir is an investigational medication that has been approved by the FDA for compassionate use in patients with COVID-19 who have developed severe or life-threatening illness. Remdesivir is an antiviral medication that is designed to prevent proliferation of the virus within the body. It has been tested in hundreds of patients with SARS-CoV-2, the virus that causes COVID-19, and preliminary results suggest that the medication may improve clinical outcomes and prevent further disease progression. This study is sponsored by Gilead Science, Inc.


Principal Investigator(s)

Todd Freudenberger, MD


Contact

Michael Bowie, michael.bowie@overlakehospital.org
 

Learn More

A full description of this study can be found at https://www.clinicaltrials.gov using NCT04323761 as the identifier. 
 

Location

Overlake Medical Center
1035 116th Ave. NE
Bellevue, WA 98004